PAR-22-167: Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Closed
This grant is closed. A newer notice from the same program is open now: Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional) (PAR-25-296). Status: Due dates in the notice, expires October 19, 2027. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to colleges and universities. Applications closed on October 17, 2024.
From the official notice on Grants.gov, last changed May 9, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG3 / UH3
- Clinical trialsOptional
- Funded byNCATS
- Median yearly award$1.0 million
- Typical project length3 years
- UG3, Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Other open UG3 notices.
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under PAR-22-167 were run by National Center for Advancing Translational Sciences (NCATS, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-167 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-25-296 | December 11, 2024 | Due dates in the notice, expires October 19, 2027 | Open |
Key dates
| Posted | May 9, 2022 |
|---|---|
| Deadline | October 17, 2024 |
| Archived by Grants.gov | November 22, 2024 |
Who can apply
This opportunity was open to colleges and universities.
- Public and State controlled institutions of higher education
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the money in the 6 programs behind this notice (78% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The Clinical and Translational Science Award (CTSA) Program Collaborative and Innovative Acceleration Award (CCIA) supports synergistic activities that accelerate the translational research process through collaboration and innovation. This funding opportunity announcement (FOA) invites applications to develop, demonstrate and disseminate innovative solutions to transform the field of translational science by addressing the inefficiencies that are common across diseases and bringing more interventions to all people more quickly through collaborative science among the CTSA Program hubs, NIH Institutes, Centers, Offices (ICOs) and/or external stakeholders.
Funded under PAR-22-167 so far
NIH funded 4 projects under PAR-22-167 in fiscal 2023 to 2026, at 3 institutions. The median yearly award was $1.0 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Bytes to Bedside: Collaborative Development for Translational Clinical Decision Support | Wake Forest University Health Sciences | 2026 | $951,167 |
| Improving Clinical Trial Efficiency and Quality: Randomized Controlled Evaluations of Remote vs. In-Person Methods | State University of New York at Buffalo | 2026 | $1.0 million |
| Integration and interoperability of complex data and tissues from the human brain | University of Illinois at Chicago | 2025 | $1.0 million |
| Improving Clinical Trial Efficiency and Quality: Randomized Controlled Evaluations of Remote vs. In-Person Methods | State University of New York at Buffalo | 2025 | $1.0 million |
Who has won Biomedical Research and Research Training grants before
From fiscal 2021 to 2025, Biomedical Research and Research Training (93.859) awarded $15 billion across 11,631 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 186 | $290 million |
| Regents of the University of Michigan | Michigan | 226 | $268 million |
| University of California, San Diego | California | 198 | $264 million |
| Yale Univ | Connecticut | 195 | $250 million |
| University of Wisconsin System | Wisconsin | 169 | $241 million |
Who has won Child Health and Human Development Extramural Research grants before
From fiscal 2021 to 2025, Child Health and Human Development Extramural Research (93.865) awarded $6.0 billion across 6,026 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 167 | $178 million |
| The Johns Hopkins University | Maryland | 133 | $146 million |
| University of Washington | Washington | 114 | $131 million |
| Baylor College of Medicine | Texas | 116 | $124 million |
| The Leland Stanford Junior University | California | 104 | $116 million |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Other programs behind this notice
- Arthritis, Musculoskeletal and Skin Diseases Research
- Minority Health and Health Disparities Research
- Oral Diseases and Disorders Research
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-25-296, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-167 still open?
No. It closed on October 17, 2024. A newer notice is open: PAR-25-296, due dates in the notice, expires October 19, 2027.
Who can apply for Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)?
National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)?
Closed October 17, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-167?
NIH RePORTER lists 4 projects funded under PAR-22-167 in fiscal 2023 to 2026, at 3 institutions. The most were at State University of New York at Buffalo, Wake Forest University Health Sciences, University of Illinois at Chicago.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)